Results 21 to 30 of about 3,746,463 (320)
ACR Open Rheumatology, 2021 Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying ...
J. Kremer +14 more
semanticscholar +1 more source
COVID-19 Therapy: the Role of Antirheumatic Drugs
Антибиотики и Химиотерапия, 2021 Currently, the close attention of the medical and international community is still riveted on the novel coronavirus infection, which caused the pandemic in 2020.
M. A. Litvinova +2 more
doaj +1 more source
Annals of the Rheumatic Diseases, 2021 Patients with rheumatic diseases are at increased risk of infectious complications; vaccinations are a critical component of their care. Disease-modifying antirheumatic drugs may reduce the immunogenicity of common vaccines. We will review here available
M. Friedman, J. Curtis, K. Winthrop
semanticscholar +1 more source
12. Toxicity of antirheumatic drugs [PDF]
Medical Journal of Australia, 1997 Pharmacological treatments can have a major impact on the outcome of rheumatic diseases. To achieve the best results, individual treatment regimens comprising analgesic agents, non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are used.
Lehmann, T., Day, R. O., Brooks, P. M.
openaire +3 more sources
Annals of the Rheumatic Diseases, 2021 Objective To estimate the incidence of psoriatic arthritis (PsA) in patients with psoriasis who had received a continuous treatment with biological disease-modifying antirheumatic drugs (bDMARDs) compared with phototherapy.
P. Gisondi +4 more
semanticscholar +1 more source
Recent advances: rheumatology [PDF]
, 2000 No abstract ...
Madhok, R., Kerr, H., Capell, H.A.
core +6 more sources
Annals of the Rheumatic Diseases, 2020 Objectives To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field.
J. Smolen +46 more
semanticscholar +1 more source
Administration of antirheumatic drugs. [PDF]
Annals of the Rheumatic Diseases, 1976 A study of 200 rheumatic patients attending an outpatient clinic and 72 general practitioners (GPs) was undertaken in relation to the administration of antirheumatic drugs. (1) Both patients and GPs agreed that effectiveness, absence of toxicity, and once daily administration were the important features of administration.
R Hopkins, V Wright
openaire +2 more sources
Antirheumatic drugs and COVID-19: frustrations and hopes
Медицинский совет, 2021 In accordance with current views on the pathogenesis of the new coronavirus infection, some antirheumatic drugs are considered as therapeutic agents for suppressing the hyperinflammatory response in severe COVID-19. The review presents literature data on
E. S. Aronova, B. S. Belov
doaj +1 more source
BMC Musculoskeletal Disorders, 2020 Background Surgical site infections are more frequent among patients with rheumatic disease. To what extent this is related to immunosuppressive antirheumatic drugs is unclear, as is the value of discontinuing medication perioperatively. The aim of study
Ylva Borgas +3 more
doaj +1 more source